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In acute myeloid leukemia (AML) the functional abnormalities of osteopontin (OPN), NF-kB, PI3K/AKT/mTOR/PTEN pathway 
or β-catenin have been considered. Aim: To analyze the response of U937 cells to parthenolide (PTL) through the involvement 
of expression of OPN protein, RelB, AKT1, mTOR, PTEN and β-catenin genes. Materials and Methods: The U937 cells were 
treated with PTL at concentrations of 4 μM (IC25) or 6 μM (IC50) and with OPN siRNA for MTT assay and colony forming 
assay. Western blot analysis using antibodies against OPN was performed with lysates of PTL-treated cells. Quantitative real-time 
polymerase chain reaction was performed using primers for OPN siRNA, RelB, AKT1, mTOR, PTEN and β-catenin. Results: PTL 
reduces OPN protein level and down-regulates RelB mRNA in U937 cell line. Suppression of OPN with siRNA increases the cy-
totoxic effects of PTL. Also, mRNA expression of AKT1, mTOR, PTEN, and β-catenin decreases with PTL or OPN siRNA. Con-
clusion: Sensitivity of U937 cells to PTL can be associated with the reduction in expression of prosurvival mediators.
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The varying response of acute myeloid leukemia 
(AML) cells to apoptosis-inducing agents reflects the 
heterogeneous biological nature of AML [1]. Generally, 
an apoptosis evasion can be achieved by activating 
anti-apoptotic molecules. Phosphoinositide 3-kinases 
(PI3Ks) regulate a variety of important cellular func-
tions, such as growth, cell cycle progression, apopto-
sis. Human leukemic cells display abnormal regulation 
of crucial factor in PI3Ks pathway, which will be useful 
to interpret the mechanisms of resistance to the con-
ventional class of chemotherapeutic agents [2].
The functional abnormalities of osteopontin (OPN), 
nuclear factor-κB (NF-κB), PI3K/AKT/mTOR/PTEN 
pathway or β-catenin have been considered as the 
crucial factors in drug resistance [2–5].
OPN is a glycoprotein expressed by cells in a va-
riety of tissues, including hematopoietic cells [6, 7]. 
The OPN transcript has been detected in metastatic 
cancer cell line [8]. The increased serum level of OPN 
in AML cells could be used as a prognostic marker [3].
NF-kB is a protein complex including RelA/p65 and 
RelB that controls transcription, cytokine production 
and cell survival [9]. In the alternative (or noncanoni-
cal) NF-κB pathway, NF-κB2 p100/RelB complexes are 
inactive in the cytoplasm [10]. RelA induces RelB gene 
transcription and mediates the stimuli-driven increase 
in RelB transcription [11]. RelB by a motif unique 
among the NF-κB family, leucine zipper motif, could 
have an extra link with various DNA sequences [12] 
and a number of physiologic responses [13].
The role of RelB in the promotion of tumor cell 
survival and correlation with high expression level 
of antiapoptotic NF-kB target genes in multiple my-
eloma has been reported [14]. The expression of RelB 
mRNA and protein in monocytes, macrophages, and 
neutrophils is inducible [11].
The PI3K/AKT/mTOR pathway is an important 
intracellular signaling pathway regulating the cellular 
quiescence and proliferation. The molecules of this 
pathway are constitutively activated in many types 
of cancer [15].
β-catenin protein is imported into the nucleus 
and activates transcription of target genes including 
cyclin D1 and c-MYC. Aberrant activation of the Wnt/β-
catenin pathway contributes to carcinogenesis and 
malignant behavior, and Wnt signaling is essential for 
the maintenance of cancer stem cells [16]. In addition, 
genetic inactivation of PTEN also leads to constitutive 
activation of the PI3K/AKT/mTOR axis [2, 17].
Knowledge of alternative therapies realizing their 
functional characteristics may provide new approach-
es to sensitize malignant cells. Therefore, considering 
functions of the above mentioned mediators involved 
in malignancies, an alternative therapy such as par-
thenolide (PTL) targeting the expression of these mol-
ecule may be useful as an effective treatment for AML.
PTL is a natural sesquiterpene lacton from Tana-
cetum parthenium (feverfew). PTL can interact with 
nucleophilic sites on biological macromolecules. Stud-
ies on this extract have suggested that it induces apop-
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tosis in leukemic cells [18–20]. PTL exerts apoptosis, 
inhibition of cell proliferation or antitumor activity either 
through NF-kB inhibition and/or possibly by other 
mechanisms [20, 21] including activation suppression 
of Akt and mTOR [22], blocking of STAT3 activity [23] 
and increase in reactive oxygen species [24].
In the present study, we tried to analyze the re-
sponse of myelomonocytic leukemic U937 cells [25] 
to PTL through expression of cytoprotective mediator 
OPN protein, RelB, AKT1, mTOR, PTEN and β-catenin 
genes. In addition, we examined whether inhibition 
of OPN mRNA can affect the viability, proliferation, 
and transcription of the above-mentioned pro-survival 
genes in U937 cells.
MATERIALS AND METHODS
Reagents. PTL purchased from Sigma-Aldrich 
(Sigma-Aldrich, St. Louis, MO) was dissolved in di-
methyl sulfoxide (DMSO) as a 50 mM stock solution, 
stored at –20 °C and diluted in the distilled water prior 
to use. The IgG2a mouse anti-human OPN and mouse 
anti-human β-actin monoclonal antibodies, as well 
as the horseradish peroxidase-conjugated secondary 
goat anti-mouse IgG antibody were purchased from 
R&D Systems (R&D System, Minneapolis, MN). TriPure 
isolation Reagent was purchased from Roche Applied 
Science (Penzberg, Germany). The cDNA synthesis 
kit and SYBR ® Premix Ex Taq™ were purchased from 
Takara Biotechnology Co (Otsu, Japan).
Cell culture. The human myelomonocytic leu-
kemic U937 cell line was obtained from the Pasteur 
Institute of Iran and cultured in RPMI 1640 with 10% 
FBS (Gibco, Carlsbad, CA). The medium were supple-
mented with 2 mM L-glutamine, 100 units/ml penicillin 
and 100 μg/ml streptomycin. Cells were incubated 
at 37 °C in a humidified atmosphere containing 5% CO2.
MTT assays. U937 cells were cultured in triplicate 
at 5•103/100 μl in 96-well culture plates (SPL Life sci-
ences, Pocheon, Korea). The cells were treated with 
different concentrations of PTL based on determined 
IC25 or IC50 in our previous study [26]. After incubation 
(37 °C, 5% CO2), the cells were incubated for 4 h with 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, 5 mg/ml) (Sigma-Aldrich, St. Louis, 
MO). The plates were spun, and the purple formazan 
crystals of yellow tetrazolium salt metabolized by vi-
able cells were dissolved in DMSO. Absorbance was 
quantified at 570 nm using the ELISA plate reader 
(Microplate Reader; Bio-Rad, USA). Results were 
expressed as a percentage of viability, with 100% rep-
resenting control cells treated with 0.1% DMSO alone.
Colony forming assay. U937 cells were sus-
pended at a density of 2000 cells in 0.5 ml of RPMI 
1640, and then treated with PTL alone or simultane-
ously in combination with OPN siRNA. The treated and 
untreated cell line were plated in Methocult semisolid 
media (Stem Cell Technologies, Vancouver, BC, Cana-
da). After 14–16 days incubation, the colonies were 
enumerated by inverted microscope. Accumulation 
of ≥ 50 cells was scored as granulocyte-macrophage 
colony-forming units and collection of 3–50 cells was 
considered as one cluster. Three independent experi-
ments were performed.
W e s t e r n  b l o t t i n g  a n a l y s i s .  T h e  c e l l s 
(1•106 cells/ml) were incubated with 4 μmol/l PTL for 
24 h. Then cells were lysed in the lysis buffer contain-
ing 1.0% Nonidet P-40, 150 mM NaCl, 20 mM Tris-HCl 
(pH 7.5), 5 mM EDTA, and a protease inhibitor mixture 
tablet Complete (Roche Diagnostics, Indianapolis, IN). 
Extracted proteins (60 μg) were loaded on SDS-PAGE 
and transferred on PVDV Membrane (Roche). After that 
the membranes were blocked by skimmed milk (Merck) 
and immunoblotted with mouse anti-human OPN and 
mouse anti-human β-actin antibodies. Membranes 
were visualized using an appropriate horseradish per-
oxidase-conjugated secondary antibody and enhanced 
chemiluminescence Western blotting detection system 
(Roche Diagnostics, Indianapolis, IN).
Quantitative real-time polymerase chain reac-
tion (qRT-PCR). Total RNA of the PTL-treated and un-
treated cell line was extracted with TriPure isolation re-
agent according to the manufacturer’s instruction. The 
cDNA synthesis kit was used for complementary DNA 
(cDNA) synthesis. A light cycler instrument (Roche 
Diagnostic, Manheim, Germany) and SYBR Premix 
Ex Taq were used for quantitative real-time analysis. 
A final volume of 20 μl containing 2 μl of a 2-fold diluted 
cDNA, 1 μl of 10 pmol primers (0.5 μl each forward and 
reverse primers), 10 μl of SYBER and 7 μl distilled water 
were used. Data were normalized to HPRT expression 
in each sample. Analysis of relative gene expression 
data were performed using the 2-∆∆Ct method. The Table 
shows the primer sequences for genes used.
Table. The primers used in qRT-PCR
Gene Forward primer (5'–3') Reverse primer (5'–3')
HPRT TGGACAGGACTGAACGTCTTG CCAGCAGGTCAGCAAAGAATTTA
OPN ACCCTTCCAAGTAAGTCCAACG GGTGAGAATCATCAGTGTCATCTAC
NF-B/RelB GCCTGACTTTGAGGGACTGTA CTAGATGCAAGGCTGTTCGTC
AKT1 AGCGACGTGGCTATTGTGAAG GTACTCCCCTCGTTTGTGCAG
mTOR AACTCCGAGAGATGAGTCAAGA AGTTGGTCATAGAAGCGAGTAGA
PTEN TGGATTCGACTTAGACTTGACCT TTTGGCGGTGTCATAATGTCTT
β-Catenin TACCTCCCAAGTCCTGTATGAG TGAGCAGCATCAAACTGTGTAG
RNA interfering. The siRNA against OPN was ap-
plied to PTL-treated cells using lipofectamin 2000 re-
agent (LF2000; 10 μg/ml; Invitrogen), according to the 
manufacturer’s instruction. Cells were lysed 24 h post-
transfection and quantitative real-time RT-PCR was 
performed using following sequences of OPN siRNA 
primers: 5´-CCAAGUAAGUCCAACGAAA (dTdT)-3´ 
(sense) and 5´-UUUCGUUGGACUUACUUGG (dTdT)-
3´(anti-sense). Highest transfection efficiency with 
minimal effects on cell viability was obtained in op-
timization experiments within 24 h post-transfection 
at a final concentration 40 pmol/ml and we used these 
optimal conditions for subsequent experiments with 
test siRNAs.
Statistical analysis. Using IBM SPSS Statis-
tics 19 software the groups of data were presented 
as means ± SD and compared by one-way analysis 
of variance (ANOVA).
32 Experimental Oncology 39, 30–35, 2017 (March)
RESULTS
PTL reduces OPN protein in U937 cells. To de-
termine the effects of PTL on transcriptional activity 
of OPN as a putative cell resistance factors in response 
to chemotherapy, we investigated protein levels of OPN 
by Western blotting analysis. The results showed that 
PTL at concentration of 4 μM (IC25 value for U937) can 
reduce OPN protein in U937 cells (Fig. 1). This confirms 
our previous study in which OPN mRNA levels decrease 
was shown by qRT-PCR [26].
Untreated PTL4
OPN
β-actin
Fig. 1. Western blotting analysis shows decrease in OPN protein 
level in PTL-treated U937 cells
PTL decreases NF-kB/RelB mRNA expression 
in U937 cells. NF-kB/RelB gene expression was sig-
nificantly attenuated in PTL-treated U937 cells (Fig. 2). 
This finding implies a concurrence between OPN and 
NF-kB/RelB expression. In the other words, PTL might 
reduce the expression of both OPN and NF-kB/RelB 
either by separate mechanisms or in some way related 
to each other.
0
0.2
0.4
0.6
0.8
1
1.2
PTL0 PTL4
*
No
rm
al
ize
d 
fo
ld
 c
ha
ng
e
NF-kB/RelB expression
Fig. 2. PTL treatment decreases NF-kB/RelB expression 
in U937 cells. Evaluation of mRNA expression of OPN relative to HPRT, 
using RT-PCR after treatment of U937 cells with PTL for 24 h. Three 
independent experiments were performed (mean ± SD). *p < 0.05
Suppression of OPN with siRNA increases the 
cytotoxic effects of PTL on U937 cells. To investigate 
whether the OPN gene knockdown decreases the cell 
viability and proliferation after PTL addition, we used 
optimized OPN siRNA. The PTL treatment subsequently 
after OPN siRNA addition decreased the cell viability and 
clonogenic growth compared with the control (without 
siRNA and PTL treatment) in U937 cells (Fig. 3). These 
observations imply that OPN plays an important role 
in the regulation of survival and proliferation of AML cells.
PTL and OPN siRNA decreases the mRNA ex-
pression of AKT, mTOR, PTEN, and β-catenin. To in-
vestigate the further involvement of the OPN expression 
concerned with PTL effects on expression of some 
crucial mediators, which are necessary toward cell 
proliferation and survival (i.e. AKT1, mTOR, β-catenin 
and PTEN), we examined the effects of OPN suppres-
sion by siRNA on transcription of those genes. Either 
OPN siRNA or PTL alone or co-treatment of OPN siRNA 
with PTL in comparison with non-treatment control re-
duced the expression of those molecules in U937 cells. 
It suggests that OPN may play a role in controlling the 
expression of those genes. Given that OPN siRNA re-
duces expression of all four genes to near-undetectable 
levels, it could be deduced that PTL failed to impact 
overall gene expression (Fig. 4).
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Fig. 3. Suppression of OPN with siRNA increases the cytotoxic 
effects of PTL on U937 cells. Transfection of U937 cells with OPN 
siRNA or treatment with PTL displayed a decrease in (a) the viability 
percent and (b) the colony formation count compared with untreat-
ed cells. Three independent experiments were performed (mean 
± SD). *p < 0.05, **p < 0.01, ***p < 0.001 (compared with control)
DISCUSSION
In our previous work concerning PTL effect on OPN 
gene expression in U937 cells we were faced with 
OPN reduction [26]. The present study showed that 
OPN is also attenuated in protein levels in PTL-treated 
U937 cells. We found that suppression of OPN with 
siRNA decreased the viability and colony-forming 
ability of U937 cells in presence of PTL.
When a malignant cell resists to chemotherapeu-
tic agents, the relapse and failure in treatment can 
occur [27]. Several relatively recent studies have 
pointed to PTL as a novel antileukemic agent that can 
selectively eliminate LSCs and progenitor cells [19, 
20]. Nonetheless some mediators bestow a resis-
tance to apoptosis advantage upon the PTL-treated 
cells [28]. The effects of high expression of OPN 
on leukemogenesis and cell protection from cytotoxic 
agents have been presented [29]. Besides, the studies 
on HL-60 cells give evidence that leukemia cells may 
produce OPN mRNA [8, 30]. Therefore, OPN might 
be involved in the PTL effects in some hematopoietic 
malignancies.
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We found that the vulnerability of U937 cells to PTL 
increases when OPN gene expression is inhibited. The 
reductive effect of PTL on OPN expression in U937 cells 
could be attributable to inhibition of transcription 
factor AP-1 as known OPN transcriptional activator, 
alike what has been reported in cystic fibrosis [31]. 
In addition, the proapoptotic potency of PTL in cancer 
cells is expressed interfering directly or indirectly with 
crucial proteins that function as gene transcriptional 
regulatory units, especially with NF-kB [32, 33]. In our 
work, PTL could be involved in the gene transcription 
of NF-kB/RelB consistent with OPN gene expression 
mode in U937 cells. There is a number of reports of a NF-
kB binding site on OPN promoter and the mutual relation 
between OPN expression and NF-kB activation [34–37].
PTL can induce apoptosis in leukemic cells through 
additional mechanisms such as PI3K pathway sup-
pression, induction of reactive oxygen species, and 
activation of stress response proteins [22, 24, 38–40]. 
We also observed that PTL decreased the mRNA le-
vels of AKT, mTOR, β-catenin and PTEN in U937 cells. 
These genes are oncogenes or tumor suppressor 
genes that have important role in the control of the cell 
cycle or apoptosis and they are frequently activated 
or suppressed in AML [41]. The suppressing effect 
of PTL on AKT/mTOR activation in malignancies has 
been already reported [22, 38, 42, 43]. According 
to UCSC genome browser on human, there are several 
binding sites of NF-kB in the AKT and PTEN promoter 
region that might have been intervened in PTL effects. 
The interferential role of the transcription factors that 
may be common for these mediators (STAT3 as an ex-
ample) could exert subtractive effects of PTL on their 
transcription. There is an AP-1 binding site in AKT pro-
moter region and with regard to afore-mentioned this 
suggests a possible route toward AKT transcriptional 
inhibition by PTL [31, 44–46]. There is an evidence 
of the inhibitory effect of PTL on the ERK pathway, 
which in turn activates proto-oncogenic transcrip-
tion factor TCF employing β-catenin to induce gene 
expression [31, 47]. Given that PTEN is an opponent 
for AKT/mTOR and subsequently for β-catenin as well 
as OPN, the levels of its expression might be coincided 
with them as seen in association of the activation of Akt 
and OPN with the PTEN activation [48]. The aberrant 
transcripts of PTEN in U937 have been reported [49], 
then the lower viability in PTL-treated U937 cells could 
be attributed to PTEN deficiency the same as in PTEN-
deficient myeloma cells being more sensitive to mTOR 
inhibition with accompanying reduction in viability [50].
In view of the more pronounced reduction of the 
above mentioned mRNA levels in cells transfected with 
OPN siRNA in comparison with untreated or PTL-exposed 
cells, it seems that OPN plays a role in the mechanisms 
of the transcription of these genes. To our knowledge, 
no other investigation has been conducted in associa-
tion between OPN and transcriptional regulation of our 
studied genes. However, the role of OPN in activation 
of the intracellular PI3K/Akt signal pathway following 
binding to avβ3 integrin or CD44 has been described 
[51–53]. Also, there is a report that OPN induces mTOR 
phosphorylation at Ser-2448 [37]. Besides, an overall in-
crease in β-catenin protein levels with a resultant transfer 
of β-catenin to the nucleus subsequent to OPN-induced 
Akt activation has been suggested [54]. There are others 
reports implying OPN participation in transcription of vari-
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Fig. 4. PTL and OPN siRNA decrease the mRNA expression of AKT, mTOR, β-catenin or PTEN. The effects of OPN suppression 
by siRNA on transcription of AKT1, mTOR, β-catenin and PTEN genes, relative to HPRT, were analyzed by quantitive RT-PCR. Three 
independent experiments were performed (mean ± SD). *p < 0.05, **p < 0.01, ***p < 0.001 (compared with control)
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ous genes that can be exerted by multiple pathways 
including PI3K/AKT, Wnt-β-catenin, P70S6K/mTOR, and 
IκBα/IKK [37, 54, 55].
In summary, the sensitivity of U937 cells to PTL can 
be associated with the reduced expression of prosur-
vival mediators such as OPN, AKT1, mTOR or β-catenin.
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